460 reports of this reaction
2.4% of all POLATUZUMAB VEDOTIN reports
#8 most reported adverse reaction
DRUG INEFFECTIVE is the #8 most commonly reported adverse reaction for POLATUZUMAB VEDOTIN, manufactured by Genentech, Inc.. There are 460 FDA adverse event reports linking POLATUZUMAB VEDOTIN to DRUG INEFFECTIVE. This represents approximately 2.4% of all 19,009 adverse event reports for this drug.
Patients taking POLATUZUMAB VEDOTIN who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a less commonly reported adverse event for POLATUZUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to drug ineffective, the following adverse reactions have been reported for POLATUZUMAB VEDOTIN:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 460 FDA reports for POLATUZUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 2.4% of all adverse event reports for POLATUZUMAB VEDOTIN, making it a notable side effect.
If you experience drug ineffective while taking POLATUZUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.